Group 1 - The core business of the company is the research, manufacturing, and sales of pharmaceutical products, with a focus on various injection solutions and capsules, many of which are unique in the market and covered by national health insurance [2] - The company reported a revenue of 1.00 billion yuan for Q1 2025, showing a year-on-year decrease of 0.46%, and a net profit loss of approximately 11.90 million yuan, reflecting a significant year-on-year decline of 960.04% [3] - The company's gross profit margin stands at 66.62%, indicating a relatively high profitability despite the revenue decline [3] Group 2 - As of June 24, the company's stock price closed at 5.8 yuan, with a rolling price-to-earnings (PE) ratio of 36.05, which is lower than the industry average PE of 54.23 [1][3] - The total market capitalization of the company is approximately 51.03 billion yuan, ranking it 96th in the chemical pharmaceutical industry based on PE ratio [1][3] - Over the past five days, the company experienced a net outflow of main funds amounting to 8.51 million yuan, indicating a trend of capital withdrawal [1]
ST景峰收盘上涨1.05%，滚动市盈率36.05倍，总市值51.03亿元
Sou Hu Cai Jing·2025-06-24 08:39